Projects per year
Personal profile
Expertise
-
I was trained as a biomedical researcher at the Vrije Universiteit Brussel (VUB), and completed my PhD in 2006 in the Hematology and Immunology (HEIM) lab, headed by Prof. Vanderkerken on the role of chemokines in Multiple Myeloma. Thereafter, I performed a 1-year post-doctoral stay at the Weill Medical College of Cornell University (USA) at the lab of Prof. S. Chen-Kiang on the topic of cell cycle regulation in MM cells. In 2007, I returned to the HEIM lab to set-up my own research team. My team utilizes in-depth cancer biology techniques and has access to the 5TMM models, fully syngeneic in vivo models to investigate MM biology. The goal of my team is to identify novel mechanisms of myeloma development and drug resistance and translate these findings into novel therapeutic targets. Since 2015, I hold a Faculty Position (Research Professor) at the VUB.
My major contributions to the field include the characterization of how exosomal crosstalk is involved in MM pathobiology (8 papers with 1 Blood paper); identification of metabolic vulnerabilities in MM cells as novel therapeutic targets to treat MM patients (6 papers with the latest in Haematologica) and identifying NKT cells as an immunotherapeutic cell type in MM (4 papers, 1 Leukemia, 1 Haematologica).
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
ANI411: Elucidating immune suppressive mechanisms against CAR T therapy
1/01/25 → 31/12/28
Project: Fundamental
-
ANI374: Targeting pro-tumoral exosomal exchanges with CD138-syntenin inhibitors : a novel therapeutic approach for Multiple Myeloma
1/01/24 → 31/12/27
Project: Fundamental
-
SRP84: SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell Therapy
Vanderkerken, K., Breckpot, K. & Menu, E.
1/11/22 → 31/10/27
Project: Fundamental
-
OZR3983: Bilateral cooperation within the framework of a joint doctoral project: benchfee for joint PhD VUB - KU Leuven, TU Chenggong
7/07/22 → 6/07/26
Project: Fundamental
-
OZR3565: Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization system
Massie, A., Stiens, J., Van Ginderachter, J., Vanommeslaeghe, K., Vinken, M., Menu, E., Spits, C. & Njemini, R.
1/05/20 → 30/04/26
Project: Fundamental
-
Correction to: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (Journal of Hematology & Oncology, (2024), 17, 1, (128), 10.1186/s13045-024-01636-4)
Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., Khassawna, T. E., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M., Kampschulte, M., & 6 others , 24 Jan 2025, In: Journal of Hematology & Oncology. 18, 1, 1 p., 11.Research output: Contribution to journal › Comment/debate
Open Access -
Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy
Zhan, D., Du, Z., Zhang, S., Huang, J., Zhang, J., Zhang, H., Liu, Z., Menu, E. & Wang, J., Jan 2025, In: Advanced Science. 12, 4, 18 p., 2408373.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Targeting MAT2A alters the methylation landscape and DNA damage response in Multiple Myeloma, revealing novel combination strategies.
Van Hemelrijck, L. A., Wang, Y., Muylaert, C., Olsen, C., De Veirman, K., Vanderkerken, K., Menu, E. & De Bruyne, E., 7 Feb 2025. 1 p.Research output: Unpublished contribution to conference › Poster
-
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse
Muylaert, C., Van Hemelrijck, L. A., Van der Vreken, A., Heestermans, R., Satilmis, H., Verheye, E., Alaterre, E., Olsen, C., De Beule, N., De Veirman, K., Menu, E., Vanderkerken, K., Moreaux, J. & De Bruyne, E., 17 Apr 2025, In: Journal of Experimental & Clinical Cancer Research. 44, 1, 18 p., 125.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Adrenergic signaling activates the tumor immune microenvironment in Multiple Myeloma
Satilmis, H., Verheye, E., Vandewalle, N., De Bruyne, E., Menu, E., Vanderkerken, K. & De Veirman, K., 23 Oct 2024, (Unpublished).Research output: Unpublished contribution to conference › Poster
Datasets
-
Dataset of AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N. (Creator), Satilmis, H. (Creator), Verheye, E. (Creator), Wang, Y. (Creator), De Groof, T. (Creator), Bridoux, J. (Creator), Kerre, T. (Creator), De Beule, N. (Creator), De Becker, A. (Creator), De Bruyne, E. (Creator), Menu, E. (Creator), Vanderkerken, K. (Creator), Breckpot, K. (Creator), Devoogdt, N. (Creator) & De Veirman, K. (Creator), Theranostics, 15 Apr 2024
DOI: 10.7150/thno.91456, https://zenodo.org/records/15111364
Dataset
Prizes
-
-
ASH abstract achievement award
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 12 Dec 2021
Prize: Prize (including medals and awards)
-
ASH abstract achievement award
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 9 Dec 2022
Prize: Prize (including medals and awards)
-
Best oral presentation
Oudaert, Inge (Recipient) & Menu, Eline (Recipient), 25 Jun 2019
Prize: National/international honour
-
Best Oral Presentation - MOSA conference 2021
Janssens, Edith Maria (Recipient), De Beck, Lien (Recipient), Verbeke, Rein (Recipient), Lentacker, Ine (Recipient), Dewitte, Heleen (Recipient), Menu, Eline (Recipient) & Breckpot, Karine (Recipient), 23 Jun 2021
Prize: Prize (including medals and awards)
File
Activities
-
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Niels Vandewalle (Presenter), Hatice Satilmis (Contributor), Emma Verheye (Contributor), Yanmeng Wang (Contributor), Timo De Groof (Contributor), Nathan De Beule (Contributor), Tessa kerre (Contributor), Nathan De Beule (Contributor), Ann De Becker (Contributor), Elke De Bruyne (Contributor), Eline Menu (Contributor), Karin Vanderkerken (Contributor), Karine Breckpot (Contributor), Nick Devoogdt (Contributor) & Kim De Veirman (Contributor)
12 Mar 2024Activity: Talk or presentation › Talk or presentation at a conference
-
AXL targeting using Bemcentinib increases chemosensitivity in Acute Myeloid Leukemia
Niels Vandewalle (Speaker), Laura Meysman (Contributor), Nathan De Beule (Contributor), Ann De Becker (Contributor), Hatice Satilmis (Contributor), Emma Verheye (Contributor), Rong Fan (Contributor), Elke De Bruyne (Contributor), Eline Menu (Contributor), Karin Vanderkerken (Contributor), Karine Breckpot (Contributor), Nick Devoogdt (Contributor) & Kim De Veirman (Contributor)
3 Feb 2023Activity: Talk or presentation › Talk or presentation at a conference
-
TARGETING MONOCARBOXYLATE TRANSPORTER 4 REDUCES MYELOMA CELL VIABILITY IN VITRO
Inge Oudaert (Contributor), Eline Menu (Presenter) & Lauren Van Droogenbroeck (Presenter)
3 Mar 2021 → 6 Mar 2021Activity: Talk or presentation › Talk or presentation at a conference
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker), Eline Menu (Contributor) & Kim De Veirman (Contributor)
29 Jan 2021 → 30 Jan 2021Activity: Talk or presentation › Talk or presentation at a conference
-
Targeting of pyrroline-5-carboxylate reductase (PYCR) reduces drug resistance in multiple myeloma in vitro.
Inge Oudaert (Speaker) & Eline Menu (Speaker)
29 Jan 2021Activity: Talk or presentation › Talk or presentation at a conference
File
Press/Media
-
-
-
-
-
Opmerkelijke doorbraak in strijd tegen multipel myeloom
1/01/05
1 Media contribution
Press/Media: Other